Acer Therapeutics Inc. (ACER)

NASDAQ: ACER · IEX Real-Time Price · USD
2.11 0.06 (2.93%)
Jan 19, 2022 9:31 AM EST - Market open
Market Cap30.19M
Revenue (ttm)900,000
Net Income (ttm)-17.19M
Shares Out14.31M
EPS (ttm)-1.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume435
Open2.15
Previous Close2.05
Day's Range2.11 - 2.15
52-Week Range1.68 - 5.39
Beta1.11
AnalystsBuy
Price Target11.00 (+421.3%)
Earnings Daten/a

About ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatme...

IndustryPharmaceuticals
Founded2013
CEOChristopher Schelling
Employees30
Stock ExchangeNASDAQ
Ticker SymbolACER
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ACER stock is "Buy." The 12-month stock price forecast is 11.00, which is an increase of 421.33% from the latest price.

Price Target
$11.00
(421.33% upside)
Analyst Consensus: Buy

News

Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year?

Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.

5 days ago - Zacks Investment Research

Acer Therapeutics to Participate in January 2022 Virtual Investor Conferences

NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

4 weeks ago - GlobeNewsWire

Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms

Phase 2a trial initiation expected in Q1 2022

1 month ago - GlobeNewsWire

Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

NEWTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

1 month ago - GlobeNewsWire

Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation

Key ACER-001 formulation composition of matter patent strengthens proprietary position in U.S. until 2036 Key ACER-001 formulation composition of matter patent strengthens proprietary position in U.S. u...

2 months ago - GlobeNewsWire

Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance

The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022.

3 months ago - Zacks Investment Research

Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation

Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 Notice of allowance of ACER-001 formulation composition of matter...

3 months ago - GlobeNewsWire

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to ...

FDA sets PDUFA target action date of June 5, 2022 FDA sets PDUFA target action date of June 5, 2022

3 months ago - GlobeNewsWire

Acer Therapeutics Stock Jumps As UCD Candidate Is Under FDA Review

The FDA has accepted for review Acer Therapeutics Inc (NASDAQ: ACER) and its partner, Relief Therapeutics Holding SA's  (OTC: RLFTF) marketing application for ACER-001 (sodium phenylbutyrate) for Urea C...

3 months ago - Benzinga

Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

4 months ago - GlobeNewsWire

Opexa Therapeutics, Inc. (ACER) Reports Q2 Loss, Misses Revenue Estimates

Opexa Therapeutics, Inc. (ACER) delivered earnings and revenue surprises of 36.11% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate Update

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

5 months ago - GlobeNewsWire

Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 ...

NEWTON, Mass. and GENEVA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of ther...

5 months ago - GlobeNewsWire

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

Other symbols:CPIXORGOXNCR
6 months ago - Zacks Investment Research

Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA Meeting

Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled

7 months ago - GlobeNewsWire

What Makes Opexa Therapeutics, Inc. (ACER) a New Buy Stock

Opexa Therapeutics, Inc. (ACER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA

NEWTON, Mass. and GENEVA, Switzerland, May 25, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercializat...

7 months ago - GlobeNewsWire

Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update

NEWTON, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rar...

8 months ago - GlobeNewsWire

Acer Therapeutics to Participate in Needham Virtual Healthcare Conference

NEWTON, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious r...

9 months ago - GlobeNewsWire

Notice of Settlement of Derivative Suits

NEWTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

9 months ago - GlobeNewsWire

Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics

Relief Therapeutics Holding AG (OTCMKTS: RLFTF) and Acer Therapeutics Inc (NASDAQ: ACER) have entered into a Collaboration and License Agreement for worldwide development and commercialization of ACER-0...

9 months ago - Benzinga

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization...

Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights

9 months ago - GlobeNewsWire

ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing Higher

Acer Therapeutics (ACER) stock is on the rise Monday as investors speculate about a possible merger with Relief Therapeutics. The post ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing High...

10 months ago - InvestorPlace

What's Happening With ACER Stock, MGM Stock, XPEV Stock?

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Other symbols:MGMXPEV
10 months ago - Benzinga

Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious r...

10 months ago - GlobeNewsWire